Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 62.1 TWD 0.16% Market Closed
Market Cap: 10.2B TWD
Have any thoughts about
Tanvex BioPharma Inc?
Write Note

Net Margin
Tanvex BioPharma Inc

-3 958.9%
Current
-30 653%
Average
-7.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 958.9%
=
Net Income
-1.6B
/
Revenue
41m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
KY
Tanvex BioPharma Inc
TWSE:6541
10.2B TWD
-3 959%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
314.6B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.3B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
136.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-14%
Country KY
Market Cap 10.2B TWD
Net Margin
-3 959%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 314.6B USD
Net Margin
9%
Country US
Market Cap 141.2B USD
Net Margin
13%
Country US
Market Cap 117.3B USD
Net Margin
0%
Country US
Market Cap 105.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 136.4B AUD
Net Margin
18%
Country US
Market Cap 78.4B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
No Stocks Found

Tanvex BioPharma Inc
Glance View

Market Cap
10.2B TWD
Industry
Biotechnology

Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.

Intrinsic Value
1.89 TWD
Overvaluation 97%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 958.9%
=
Net Income
-1.6B
/
Revenue
41m
What is the Net Margin of Tanvex BioPharma Inc?

Based on Tanvex BioPharma Inc's most recent financial statements, the company has Net Margin of -3 958.9%.